{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:43:28Z","timestamp":1791279808848,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T00:00:00Z","timestamp":1190592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FEBS Journal"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:p>Enzyme enhancement therapy is an emerging therapeutic approach that has the potential to treat many genetic diseases. Candidate diseases are those associated with a mutant protein that has difficulty folding and\/or assembling into active oligomers in the endoplasmic reticulum. Many lysosomal storage diseases are candidates for enzyme enhancement therapy and have the additional advantage of requiring only 5\u201310% of normal enzyme levels to reduce and\/or prevent substrate accumulation. Our long experience in working with the \u03b2\u2010hexosaminidase (EC\u20033.2.1.52) isozymes system and its associated deficiencies (Tay\u2010Sachs and Sandhoff disease) lead us to search for possible enzyme enhancement therapy\u2010agents that could treat the chronic forms of these diseases which express 2\u20135% residual activity. Pharmacological chaperones are enzyme enhancement therapy\u2010agents that are competitive inhibitors of the target enzyme. Each of the known \u03b2\u2010hexosaminidase inhibitors (low \u00b5<jats:sc>m<\/jats:sc> IC<jats:sub>50<\/jats:sub>) increased mutant enzyme levels to \u2265\u200a10% in chronic Tay\u2010Sachs fibroblasts and also attenuated the thermo\u2010denaturation of \u03b2\u2010hexosaminidase. To expand the repertoire of pharmacological chaperones to more \u2018drug\u2010like\u2019 compounds, we screened the Maybridge library of 50\u2003000 compounds using a real\u2010time assay for noncarbohydrate\u2010based \u03b2\u2010hexosaminidase inhibitors and identified several that functioned as pharmacological chaperones in patient cells. Two of these inhibitors had derivatives that had been tested in humans for other purposes. These observations lead us to screen the NINDS library of 1040 Food and Drug Administration approved compounds for pharmacological chaperones. Pyrimethamine, an antimalarial drug with well documented pharmacokinetics, was confirmed as a \u03b2\u2010hexosaminidase pharmacological chaperone and compared favorably with our best carbohydrate\u2010based pharmacological chaperone in patient cells with various mutant genotypes.<\/jats:p>","DOI":"10.1111\/j.1742-4658.2007.06040.x","type":"journal-article","created":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T17:43:13Z","timestamp":1190655793000},"page":"4951-4961","source":"Crossref","is-referenced-by-count":57,"title":["Lending a helping hand, screening chemical libraries for compounds that enhance \u03b2\u2010hexosaminidase\u2003A activity in GM2 gangliosidosis cells"],"prefix":"10.1111","volume":"274","author":[{"given":"Michael B.","family":"Tropak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Mahuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(99)00074-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00219337"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(03)00216-X"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.04.004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2760(98)00057-5"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2000.4225"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(02)00221-1"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0029200"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)67145-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)83927-3"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85585-0"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)43301-1"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.05.110189.001425"},{"key":"e_1_2_7_15_2","first-page":"817","article-title":"Ashkenazi Jewish and non\u2010Jewish adult GM2 gangliosidosis patients share a common genetic defect","volume":"46","author":"Navon R","year":"1990","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)90623-X"},{"key":"e_1_2_7_17_2","first-page":"497","article-title":"beta\u2010Hexosaminidase isozymes from cells cotransfected with alpha and beta cDNA constructs: analysis of the alpha\u2010subunit missense mutation associated with the adult form of Tay\u2010Sachs disease","volume":"53","author":"Brown CA","year":"1993","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.60.070191.004051"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1192-1413"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.58.070189.004001"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.2006-0066"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2005.03.029"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphysparis.2005.12.012"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2006.08.024"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414043200"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2005.06.026"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.02.005"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2005.06.009"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2005.09.007"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308523200"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.12.006"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.857"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609304200"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.3.580"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.91"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1992.46.288"},{"key":"e_1_2_7_37_2","volume-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","author":"Buxton ILO","year":"2006"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg963"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00158-5"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192582899"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2006.08.012"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1128294"},{"key":"e_1_2_7_43_2","first-page":"138","article-title":"Hereditary heat\u2010labile hexosaminidase B: a variant whose homozygotes synthesize a functional hex A","volume":"37","author":"Navon R","year":"1985","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20242"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.09.043"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(06)14020-3"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(03)01069-3"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi240"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-4658.2007.06040.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-4658.2007.06040.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:36:06Z","timestamp":1697502966000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-4658.2007.06040.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,24]]},"references-count":47,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1742-4658.2007.06040.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-4658.2007.06040.x","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,24]]}}}